vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical trials; type II diabetes drug candidates include Glucokinase Activator TTP399 and GLP-1r Agonist TTP273 which completed Phase I clinical trials; products for the prevention of muscle weakness and treatment of inflammatory disorders include HPP593, HPP737 and HPP971 which is in Phase1 clinical trials. The Company's drug discovery platform consists of TTP Translational Technology. vTv Therapeutics Inc. is headquartered in High Point, North Carolina.
| Revenue (Most Recent Fiscal Year) | $1.02M |
| Net Income (Most Recent Fiscal Year) | $-18.46M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 5.87 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -134723.52% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -121.46% |
| Return on Assets (Trailing 12 Months) | -46.75% |
| Current Ratio (Most Recent Fiscal Quarter) | 7.39 |
| Quick Ratio (Most Recent Fiscal Quarter) | 7.39 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $2.79 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.77 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.20 |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.01 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 3.19M |
| Free Float | 3.06M |
| Market Capitalization | $52.26M |
| Average Volume (Last 20 Days) | 5590.20 |
| Beta (Past 60 Months) | 0.77 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 4.20% |
| Percentage Held By Institutions (Latest 13F Reports) | 17.51% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |